Loading…
Reported covered position: Rep. Holding, Legislative Director, 2014-2017; Rep. Holding, Senior Legislative Assistant, 2013-2014; Rep. Dold, Legislative Assistant, 2011-2013; Legislative Correspondent, 2011-2011
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Uyghur Forced Labor Prevention Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2021 · second_quarter · Q2
Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P.L. 116-283); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES Act) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; suggestions and proposals for the pre-markup of the 2022 National Defense Authorization Act (NDAA); FY 2022 Cybersecurity and Infrastructure Security (CISA) appropriations; FY 2022 National Defense Authorization Act and potential anti-arbitration amendments
Source: Senate LDA
Uyghur Forced Labor Prevention Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1976, Medicare for All Act of 2021 H.R. 1319, American Rescue Plan Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act Draft legislation titled No Surprises Act Potential legislation regarding COVID-19 liability issues Potential legislation similar to S. 4317, Safeguarding America's Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Comments on the Most Favored Nations (MFN); Interim Final Rule (85 Fed. Reg. 76180) Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020 Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89) (86 Fed. Reg. 8356) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); implementation of the Families First Coronavirus Response Act (P.L. 116-127); implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
American Rescue Plan Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Medicare for All Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1976, Medicare for All Act of 2021 H.R. 1319, American Rescue Plan Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act Draft legislation titled No Surprises Act Potential legislation regarding COVID-19 liability issues Potential legislation similar to S. 4317, Safeguarding America's Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Comments on the Most Favored Nations (MFN); Interim Final Rule (85 Fed. Reg. 76180) Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020 Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89) (86 Fed. Reg. 8356) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); implementation of the Families First Coronavirus Response Act (P.L. 116-127); implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Consumer Protection and Recovery Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Elijah E. Cummings Lower Drug Costs Now Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Longshore and Harbor Workers’ COVID–19 Compensation Act of 2022
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
State Antitrust Enforcement Venue Act of 2022
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
American Innovation and Choice Online Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Ending Platform Monopolies Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Platform Competition and Opportunity Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Merger Filing Fee Modernization Act of 2022
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
ACCESS Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
United States Innovation and Competition Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Ensuring Parity in MA for Audio-Only Telehealth Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1976, Medicare for All Act of 2021 H.R. 1319, American Rescue Plan Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act Draft legislation titled No Surprises Act Potential legislation regarding COVID-19 liability issues Potential legislation similar to S. 4317, Safeguarding America's Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Comments on the Most Favored Nations (MFN); Interim Final Rule (85 Fed. Reg. 76180) Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020 Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89) (86 Fed. Reg. 8356) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); implementation of the Families First Coronavirus Response Act (P.L. 116-127); implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Ensuring Parity in MA for Audio-Only Telehealth Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Health Savings Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Uyghur Forced Labor Prevention Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Uyghur Forced Labor Prevention Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
Trade Security Act of 2021
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Endless Frontier Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
Endless Frontier Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
SAFE TO WORK Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1976, Medicare for All Act of 2021 H.R. 1319, American Rescue Plan Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act Draft legislation titled No Surprises Act Potential legislation regarding COVID-19 liability issues Potential legislation similar to S. 4317, Safeguarding America's Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Comments on the Most Favored Nations (MFN); Interim Final Rule (85 Fed. Reg. 76180) Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020 Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89) (86 Fed. Reg. 8356) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); implementation of the Families First Coronavirus Response Act (P.L. 116-127); implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
America LEADS Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan.
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 H.R. 8884, To amend the Trade Act of 1974 to modify and extend the Generalized System of Preferences, and for other purposes S. 2, Fair Trade with China Enforcement Act S. 178, Uighur Intervention and Global Humanitarian Unified Response (UIGHUR) Act of 2019 S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); Congressional action to pass technical corrections to the USMCA Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); utilization and implementation of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; USTR section 301 investigation of Frances digital service tax; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); letter to USTR urging Congress to renew the Caribbean Basin Trade Partnership Act (P.L. 106-200); comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization: Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; comments on Export-Import Bank of the United States [Public Notice: EIB-2020-0011]: Proposal To Consider Changes to EXIMs Content Policy With Respect to the Program on China and Transformational Exports; letter to 301 Proposed Rulemaking; renewal/reauthorization of the Miscellaneous Tariff Bill (MTB) Act in the Omnibus Spending Bill; Submission in response to Federal Register notice on USTR Vietnam 301 investigation; comments regarding the advance notice of proposed rulemaking concerning identification and review of controls for certain foundational technologies
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chain; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; implementation of the Merchandise Processing Fee in the USMCA; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; Executive Order 13920, Securing the United States Bulk-Power System; section 232 investigation into imports of laminations and wound cores for incorporation into transformers, electrical transformers, and transformer regulators
Trade Security Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy America executive order; effects of imports of uranium on national security
REPAY Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
REPAY Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 S. 1790, National Defense Authorization Act for Fiscal Year 2020 Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Defense Federal Acquisition Regulation Supplement (DFARS) expediting contract closeout; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
REPAY Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
REPAY Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy
REPAY Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
Medicare Buy-In and Health Care Stabilization Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Medicare Buy-In and Health Care Stabilization Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare Buy-In and Health Care Stabilization Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare Buy-In and Health Care Stabilization Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare for All Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare for All Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Medicare for All Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare for All Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Health Insurance Tax Relief Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Health Insurance Tax Relief Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Health Insurance Tax Relief Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Health Insurance Tax Relief Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient Protection and Affordable Care Enhancement Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Patient Protection and Affordable Care Enhancement Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient Protection and Affordable Care Enhancement Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient Protection and Affordable Care Enhancement Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Further Consolidated Appropriations Act, 2020
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Further Consolidated Appropriations Act, 2020
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Further Consolidated Appropriations Act, 2020
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Further Consolidated Appropriations Act, 2020
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Lower Costs, More Cures Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Lower Costs, More Cures Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Lower Costs, More Cures Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Lower Costs, More Cures Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Restoring Access to Medication Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Restoring Access to Medication Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Restoring Access to Medication Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Restoring Access to Medication Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Family Savings for Kids and Seniors Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Family Savings for Kids and Seniors Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Family Savings for Kids and Seniors Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Family Savings for Kids and Seniors Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Protect Medical Innovation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Protect Medical Innovation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Protect Medical Innovation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Protect Medical Innovation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chain; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; implementation of the Merchandise Processing Fee in the USMCA; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; Executive Order 13920, Securing the United States Bulk-Power System; section 232 investigation into imports of laminations and wound cores for incorporation into transformers, electrical transformers, and transformer regulators
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy America executive order; effects of imports of uranium on national security
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 H.R. 8884, To amend the Trade Act of 1974 to modify and extend the Generalized System of Preferences, and for other purposes S. 2, Fair Trade with China Enforcement Act S. 178, Uighur Intervention and Global Humanitarian Unified Response (UIGHUR) Act of 2019 S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); Congressional action to pass technical corrections to the USMCA Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); utilization and implementation of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; USTR section 301 investigation of Frances digital service tax; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); letter to USTR urging Congress to renew the Caribbean Basin Trade Partnership Act (P.L. 106-200); comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization: Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; comments on Export-Import Bank of the United States [Public Notice: EIB-2020-0011]: Proposal To Consider Changes to EXIMs Content Policy With Respect to the Program on China and Transformational Exports; letter to 301 Proposed Rulemaking; renewal/reauthorization of the Miscellaneous Tariff Bill (MTB) Act in the Omnibus Spending Bill; Submission in response to Federal Register notice on USTR Vietnam 301 investigation; comments regarding the advance notice of proposed rulemaking concerning identification and review of controls for certain foundational technologies
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Mongolia Third Neighbor Trade Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Medicare Prescription Drug Price Negotiation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare Prescription Drug Price Negotiation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Medicare Prescription Drug Price Negotiation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Medicare Prescription Drug Price Negotiation Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Patient-Centered Outcomes Research Extension Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient-Centered Outcomes Research Extension Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient-Centered Outcomes Research Extension Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
Patient-Centered Outcomes Research Extension Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chain; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; implementation of the Merchandise Processing Fee in the USMCA; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; Executive Order 13920, Securing the United States Bulk-Power System; section 232 investigation into imports of laminations and wound cores for incorporation into transformers, electrical transformers, and transformer regulators
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy America executive order; effects of imports of uranium on national security
United States Export Finance Agency Act of 2019
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 H.R. 8884, To amend the Trade Act of 1974 to modify and extend the Generalized System of Preferences, and for other purposes S. 2, Fair Trade with China Enforcement Act S. 178, Uighur Intervention and Global Humanitarian Unified Response (UIGHUR) Act of 2019 S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); Congressional action to pass technical corrections to the USMCA Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); utilization and implementation of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; USTR section 301 investigation of Frances digital service tax; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); letter to USTR urging Congress to renew the Caribbean Basin Trade Partnership Act (P.L. 106-200); comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization: Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; comments on Export-Import Bank of the United States [Public Notice: EIB-2020-0011]: Proposal To Consider Changes to EXIMs Content Policy With Respect to the Program on China and Transformational Exports; letter to 301 Proposed Rulemaking; renewal/reauthorization of the Miscellaneous Tariff Bill (MTB) Act in the Omnibus Spending Bill; Submission in response to Federal Register notice on USTR Vietnam 301 investigation; comments regarding the advance notice of proposed rulemaking concerning identification and review of controls for certain foundational technologies
CROOK Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
CROOK Act
Client: CHAMBER OF COMMERCE OF THE U.S.A. · Firm: CHAMBER OF COMMERCE OF THE U.S.A.
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 1976, Medicare for All Act of 2021 H.R. 3114, Longshore and Harbor Workers COVID-19 Compensation Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act S. 380, Health Savings Act of 2021 Final rule, transparency in coverage (85 Fed. Reg. 72,158 - 72,310, November 12, 2020) Interim final rule Most Favored Nation (MFN) Model (85 Fed. Reg. 76,180 - 76,259, November 27, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; vaccine diplomacy; implementation of the Consolidated Appropriations Act, 2021 (P.L. 116-260) health care provisions; implementation of the American Rescue Plan Act (P.L. 117-2); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020; Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
Nomination of Bill Nelson to be NASA Administrator Nomination of Polly Trottenberg to be Deputy Secretary of Transportation Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P.L. 116-283); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of Section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of Section 2209 of the FAA Extension Safety and Security Act of 2016 (P.L. 114-190); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-254); unmanned aerial systems, and FAA exemptions for commercial operations of UAS and urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes H.R. 2668, Consumer Protection and Recovery Act H.R. 3460, State Antitrust Enforcement Venue Act of 2021 H.R. 3816, American Choice and Innovation Online Act H.R. 3825, Ending Platform Monopolies Act H.R. 3826, Platform Competition and Opportunity Act of 2021 H.R. 3843, Merger Filing Fee Modernization Act of 2021 H.R. 3849, Augmenting Compatibility and Competition by Enabling Service Switching (ACCESS) Act of 2021 S. 65, Uyghur Forced Labor Prevention Act S. 746, Trade Security Act of 2021 S. 1260, United States Innovation and Competition Act of 2021 including issues related to SA 1495, SA 1562, SA 1565, SA 1678, and SA 1853 Draft legislation titled Protecting Americans Data from Foreign Surveillance Act Potential legislation similar to H.R. 4067 To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan (115th Congress) Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); U.S.-Korea digital trade and services; United States-Mexico-Canada (USMCA) Labor Council; Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Foreign Agents Registration Act (FARA) (P.L. 75-583); Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Kazakhstan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; establishment of an U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the Miscellaneous Tariff bill
Filing targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2021 · first_quarter · Q1
Nomination of Denis McDonough to be Secretary of Veterans Affairs Nomination of Ali Mayorkas to be Secretary of Department of Homeland Security Nomination of Lloyd Austin to be Secretary of Defense Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P.L. 116-283); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; continuation of the National Space Council
H.R. 1976, Medicare for All Act of 2021 H.R. 1319, American Rescue Plan Act of 2021 S. 150, Ensuring Parity in Medicare Advantage for Audio-Only Telehealth Act Draft legislation titled No Surprises Act Potential legislation regarding COVID-19 liability issues Potential legislation similar to S. 4317, Safeguarding America's Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Comments on the Most Favored Nations (MFN); Interim Final Rule (85 Fed. Reg. 76180) Comments on IRS Notice 2020-76; Transition Relief Related to Health Coverage Reporting Required by Sections 6055 and 6056 for 2020 Comments on COVID-19 Telehealth Program Application Evaluation Metrics (WC Docket No. 20-89) (86 Fed. Reg. 8356) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business; coronavirus pandemic; vaccine distribution, PPE, testing, medications and treatments, and vaccination incentives; digital health credentials; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); implementation of the Families First Coronavirus Response Act (P.L. 116-127); implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; drug pricing; inclusion of prescription drug pricing in the congressional agenda; COBRA subsidies; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization
H.R. 1155, Uyghur Forced Labor Prevention Act H.R. 2072, To amend the Securities Exchange Act of 1934 to require issuers to make certain disclosures relating to the Xinjiang Uyghur Autonomous Region, and for other purposes S. 65, Uyghur Forced Labor Prevention Act S. 746, A bill to amend section 232 of the Trade Expansion Act of 1962 to require the Secretary of Defense to initiate investigations and to provide for congressional disapproval of certain actions, and for other purposes Draft legislation titled Trade Security Act Potential legislation similar to H.R. 6978/S. 3832, Endless Frontier Act (116th Congress) Potential legislation similar to S. 4629, America Labor, Economic competitiveness, Alliances, Democracy and Security (America LEADS) Act (116th Congress) Nomination of Don Graves to be Deputy Secretary of Commerce Nomination of Gina Raimondo to be Secretary of Commerce Nomination of Katherine Tai to be United States Trade Representative (USTR) Nominees for the Board of Directors for the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP); North American Free Trade Agreement (NAFTA); U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP) reauthorization; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; Changes to the Lobbying Disclosure Act (LDA) (P.L.104-65) and Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P. L. 116-283); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); USTR 2021 Special 301; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; WTO Covid-19 related Trade-Related Intellectual Property Rights (TRIPS) waiver proposal; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Use of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Executive Order 14017, America's Supply Chains; Executive Order 14005, Ensuring the Future Is Made in All of America by All of America's Workers; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. trade and regulatory relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S. sanctions on Burma; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy and sustainability cooperation; U.S.-Switzerland economic and commercial relations; EU and international tax policy including digital tax proposals; Ukraine related sanctions; Indias Information Communications Technology (ICT) Tariffs; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act (P.L. 116-113); negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; ratification of the Biodiversity Convention; ratification of the Kigali Amendment to the Montreal Protocol; efforts to pass legislation to implement the Basel Convention and related instruments; efforts to pass the miscellaneous tariff bill
Nomination of Bill Nelson to be NASA Administrator Nomination of Pete Buttigieg to be Secretary of Transportation Nomination of Polly Trottenberg to be Deputy Secretary of Transportation Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 (P.L. 116-283); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of Section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS and urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · fourth_quarter · Q4
H.R. 5125/S. 2502, American Security Drone Act of 2019 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, February 13, 2020) Notice of request for comments: Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0 (AV 4.0) (85 Fed. Reg. 7,011-7,012, February 6, 2020) Notice of proposed rulemaking regarding remote identifications of unmanned aerial systems (84 Fed. Reg. 72,438-72,524, December 31, 2019) Proposed rule for Control of Air Pollution from Airplanes and Airplane Engines (85 Fed. Reg. 51,556-51,594, August 20, 2020) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of Section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); implementation Section 2209 of the FAA Extension, Safety, and Security Act of 2016 (P.L. 114-190); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 H.R. 8884, To amend the Trade Act of 1974 to modify and extend the Generalized System of Preferences, and for other purposes S. 2, Fair Trade with China Enforcement Act S. 178, Uighur Intervention and Global Humanitarian Unified Response (UIGHUR) Act of 2019 S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); Congressional action to pass technical corrections to the USMCA Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); utilization and implementation of Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; USTR section 301 investigation of Frances digital service tax; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); letter to USTR urging Congress to renew the Caribbean Basin Trade Partnership Act (P.L. 106-200); comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; negotiations on a U.S.-Brazil Trade Agreement to update the 2011 Agreement on Trade and Economic Cooperation (ATEC); supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization: Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; comments on Export-Import Bank of the United States [Public Notice: EIB-2020-0011]: Proposal To Consider Changes to EXIMs Content Policy With Respect to the Program on China and Transformational Exports; letter to 301 Proposed Rulemaking; renewal/reauthorization of the Miscellaneous Tariff Bill (MTB) Act in the Omnibus Spending Bill; Submission in response to Federal Register notice on USTR Vietnam 301 investigation; comments regarding the advance notice of proposed rulemaking concerning identification and review of controls for certain foundational technologies
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; Medicare hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; distribution of COVID-19 vaccines; comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET); reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization; COVID-19 liability issues; Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · third_quarter · 3A
H.R. 5125/S. 2502, American Security Drone Act of 2019 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, February 13, 2020) Notice of request for comments: Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0 (AV 4.0) (85 Fed. Reg. 7,011-7,012, February 6, 2020) Notice of proposed rulemaking regarding remote Identification of unmanned aerial systems (84 Fed. Reg. 72,438-72,524, December 31, 2019) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · third_quarter · 3A
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
H.R. 5125/S. 2502, American Security Drone Act of 2019 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, February 13, 2020) Notice of request for comments: Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0 (AV 4.0) (85 Fed. Reg. 7,011-7,012, February 6, 2020) Notice of proposed rulemaking regarding remote Identification of unmanned aerial systems (84 Fed. Reg. 72,438-72,524, December 31, 2019) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · third_quarter · Q3
H.R. 5125/S. 2502, American Security Drone Act of 2019 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, February 13, 2020) Notice of request for comments: Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0 (AV 4.0) (85 Fed. Reg. 7,011-7,012, February 6, 2020) Notice of proposed rulemaking regarding remote Identification of unmanned aerial systems (84 Fed. Reg. 72,438-72,524, December 31, 2019) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · second_quarter · Q2
H.R. 5125/S. 2502, American Security Drone Act of 2019 H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, January 13, 2020) Notice of request for comments: Ensuring American Leadership in Automated Vehicle Technologies: Automated Vehicles 4.0 (AV 4.0) (85 Fed. Reg. 7,011-7,012, February 6, 2020) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2020 · first_quarter · Q1
Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Request for comments on a draft memorandum to the heads of executive departments and agencies, Guidance for Regulation of Artificial Intelligence Applications (85 Fed. Reg. 1,825, January 13, 2020) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of the Foreign Assistance Act (P.L. 87-195); Implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2019 · fourth_quarter · Q4
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 1025, UIGHUR Act of 2019 H.R. 1704, Championing American Business Through Diplomacy Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; universal postal union; draft Executive Order combatting counterfeits and opioids; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2019 · third_quarter · Q3
Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); Implementation of the Foreign Assistance Act (P.L. 87-195); Implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; Reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 1704, Championing American Business Through Diplomacy Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act ]H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 S. 2, Fair Trade with China Enforcement Act S. 1004, Securing America's Ports of Entry Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); Reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; universal postal union; draft Executive Order combatting counterfeits and opioids; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; effects of imports of uranium on national security
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2019 · second_quarter · Q2
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 1704, Championing American Business Through Diplomacy Act of 2019 H.R. 3407, United States Export Finance Agency Act of 2019 S. 2, Fair Trade with China Enforcement Act S. 1004, Securing America's Ports of Entry Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to the Committee on Foreign Investment in the United States; Reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; EU tax policy including digital tax proposals; Ukraine related sanctions; Russia related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); trade policy; steel and aluminum tariffs, including on China; latest round of U.S. tariffs is a 10 percent levy on $200 billion worth of Chinese goods, which is set to rise to 25 percent by the end of the year; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; universal postal union; privacy and civil liberties oversight board; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; effects of imports of uranium on national security
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2019 · first_quarter · Q1
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 1704, Championing American Business Through Diplomacy Act of 2019 S. 2, Fair Trade with China Enforcement Act Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to the Committee on Foreign Investment in the United States; Reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; EU tax policy including digital tax proposals; Ukraine related sanctions; Russia related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank global food security strategy; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); trade policy; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; universal postal union; privacy and civil liberties oversight board; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2018 · fourth_quarter · Q4
H.R. 351, Freedom to Travel to Cuba Act of 2017 H.R. 442/S. 472, Cuba Trade Act of 2017 H.R. 525, Cuba Agricultural Exports Act H.R. 3776, Cyber Diplomacy Act of 2017 H.R. 4067, To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan H.R. 4170/S. 2309, Disclosing Foreign Influence Act H.R. 4265/S. 2086, Sugar Policy Modernization Act of 2017 H.R. 4311/S. 2098, Foreign Investment Risk Review Modernization Act of 2017 H.R. 4318/S. 2108, Miscellaneous Tariff Bill Act of 2017 H.R. 4979, To extend the Generalized System of Preferences and to make technical changes to the competitive need limitations provision of the program H.R. 5105/S. 2463, Better Utilization of Investments Leading to Development (BUILD) Act of 2018 H.R. 5515/S. 2987, John S. McCain National Defense Authorization Act for Fiscal Year 2019, including issues related to reform of the Committee on Foreign Investment in the United States and sanctions related to the government of India H.R. 5904, No Oil Producing and Exporting Cartels (NOPEC) Act of 2018 H.R. 6337/S. 3013, To amend the Trade Expansion Act of 1962 to require Congressional approval before the President adjusts imports that are determined to threaten to impair national security H.R. 6923, Promoting Responsible and Free Trade Act S. 1983, United States Foreign Investment Review Act of 2017 S. 2482, Foreign Agents Registration Amendments Act of 2018 S. 2736, Asia Reassurance Initiative Act of 2018 S. 2826, Fair Trade with China Enforcement Act S. 2987, John S. McCain National Defense Authorization Act for Fiscal Year 2019, including provisions related to the Corker/Toomey amendment to strengthen Congressional authority over tariffs, issues related to reform of the Committee on Foreign Investment in the United States, and sanctions related to the government of India S. 3013, A bill to amend the Trade Expansion Act of 1962 to require Congressional approval before the President adjusts imports that are determined to threaten to impair national security S. 3329, Trade Security Act of 2018 S. 3470, Mongolia Third Neighbor Trade Act H. Res. 60, Expressing continued support for the special relationship between the United States and the United Kingdom and urging commencement of negotiations for the development of a North Atlantic Trade and Investment Partnership (NATIP) between the United States and the United Kingdom Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to international trade agreements; Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Foreign Investment Risk Review Modernization Act of 2017 (P.L. 115-232, Title XVII); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); e-commerce issues pertaining to the World Customs Organization; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); Export-Import Bank; global food security strategy; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with China; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); trade policy; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; universal postal union; privacy and civil liberties oversight board; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114)
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2018 · third_quarter · Q3
H.R. 351, Freedom to Travel to Cuba Act of 2017 H.R. 442, Cuba Trade Act of 2017 H.R. 525, Cuba Agricultural Exports Act H.R. 2520, Balancing the Rights Of Web Surfers Equally and Responsibly (BROWSER) Act of 2017 H.R. 3776, Cyber Diplomacy Act of 2017 H.R. 4067, To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan H.R. 4170/S. 2309, Disclosing Foreign Influence Act H.R. 4265/S. 2086, Sugar Policy Modernization Act of 2017 H.R. 4311/S. 2098, Foreign Investment Risk Review Modernization Act of 2017 H.R. 4318/S. 2108, Miscellaneous Tariff Bill Act of 2017 H.R. 4943/S. 2383, Clarifying Lawful Overseas Use of Data (CLOUD) Act H.R. 4979, To extend the Generalized System of Preferences and to make technical changes to the competitive need limitations provision of the program H.R. 5105/S. 2463, Better Utilization of Investments Leading to Development (BUILD) Act of 2018 H.R. 5515/S. 2987, John S. McCain National Defense Authorization Act for Fiscal Year 2019 H.R. 5904, No Oil Producing and Exporting Cartels (NOPEC) Act of 2018 H.R. 6337/S. 3013, To amend the Trade Expansion Act of 1962 to require Congressional approval before the President adjusts imports that are determined to threaten to impair national security S. 472, Cuba Trade Act of 2017 S. 1983, United States Foreign Investment Review Act of 2017 S. 2482, Foreign Agents Registration Amendments Act of 2018 S. 2826, Fair Trade with China Enforcement Act S. 3329, Trade Security Act of 2018 H. Res. 60, Expressing continued support for the special relationship between the United States and the United Kingdom and urging commencement of negotiations for the development of a North Atlantic Trade and Investment Partnership (NATIP) between the United States and the United Kingdom Nomination of Kimberly Reed to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to international trade agreements; Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; global supply chain priorities; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); drafting of World Customs Organizations E-Commerce Framework Standards; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime, industrial policies and cyber security; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the North American Free Trade Agreement (NAFTA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S. Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. sanctions on Russia; U.S.-EU privacy shield; U.S.-EU energy relations; EU tax policy; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); Export-Import Bank; global food security strategy; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with China; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); trade policy; steel and aluminum tariffs, including on China
CHAMBER OF COMMERCE OF THE U.S.A. via CHAMBER OF COMMERCE OF THE U.S.A.
2018 · second_quarter · Q2
H.R. 351, Freedom to Travel to Cuba Act of 2017 H.R. 442, Cuba Trade Act of 2017 H.R. 525, Cuba Agricultural Exports Act H.R. 2520, Balancing the Rights Of Web Surfers Equally and Responsibly (BROWSER) Act of 2017 H.R. 3776, Cyber Diplomacy Act of 2017 H.R. 4067, To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to the products of Kazakhstan H.R. 4170/S. 2309, Disclosing Foreign Influence Act H.R. 4265/S. 2086, Sugar Policy Modernization Act of 2017 H.R. 4311/S. 2098, Foreign Investment Risk Review Modernization Act of 2017 H.R. 4318/S. 2108, Miscellaneous Tariff Bill Act of 2017 H.R. 4943/S. 2383, Clarifying Lawful Overseas Use of Data (CLOUD) Act H.R. 4979, To extend the Generalized System of Preferences and to make technical changes to the competitive need limitations provision of the program H.R. 5105/S. 2463, Better Utilization of Investments Leading to Development (BUILD) Act of 2018 H.R. 5515/S. 2987, John S. McCain National Defense Authorization Act for Fiscal Year 2019 S. 472, Cuba Trade Act of 2017 S. 1983, United States Foreign Investment Review Act of 2017 S. 2482, Foreign Agents Registration Amendments Act of 2018 S. 2826, Fair Trade with China Enforcement Act S. 3013, A bill to amend the Trade Expansion Act of 1962 to require Congressional approval before the President adjusts imports that are determined to threaten to impair national security H. Res. 60, Expressing continued support for the special relationship between the United States and the United Kingdom and urging commencement of negotiations for the development of a North Atlantic Trade and Investment Partnership (NATIP) between the United States and the United Kingdom Nomination of Kimberly Reed to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to international trade agreements; Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA); global supply chain priorities; U.S.-Korea Free Trade Agreement (KORUS); Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; World Trade Organizations Trade Facilitation Agreement (TFA), including implementation work with agencies; drafting of World Customs Organizations E-Commerce Framework Standards; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's IPR, industrial policies and cybersecurity issues; Anti-Counterfeiting Trade Agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the North American Free Trade Agreement (NAFTA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Canada Regulatory Cooperation Council (RCC); U.S. trade relations with the Middle East and North Africa; U.S. sanctions on Russia; U.S.-EU privacy shield; U.S.-EU energy relations; EU tax policy; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Overseas Private Investment Corporation (OPIC); Export-Import Bank; global food security strategy; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; bilateral investment treaty negotiations with China; bilateral investment treaty negotiations with India; tax treaties with Hungary, Poland, Chile, Switzerland, Luxembourg, Spain and Japan; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); trade policy; steel and aluminum tariffs
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 991, Extension of the Caribbean Basin Economic Recovery Act H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act H.R. 6210, Uyghur Forced Labor Prevention Act H.R. 6270, Uyghur Forced Labor Disclosure Act of 2020 H.R. 7608, State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); reauthorization of the Caribbean Basin Economic Recovery Act (P.L. 98-67); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization (WTO); Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chains; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democratic Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on CBP notice of proposed rulemaking on the Modernization of the Customs Brokers Regulations; comments on Economic Impact of Trade Agreements Implemented Under Trade Authorities Procedures (Investigation No. TPA-105-008); comments on Export-Import Bank of the United States [Public Notice: EIB-2020-003]: request to renew Partnership With Private Export Funding Corporation (PEFCO); extension of the Caribbean Basin Economic Recovery Act (P.L. 98-67); Comments on USTR request for information on China WTO Compliance; Indias non-personal data governance framework; implementation of the United States-Mexico-Canada trade agreement (USMCA), including plastics toxicity under the Canadian Environmental Protection Act; issues related to a potential U.S.-Brazil Trade Deal; comments on Section 301 Investigation of Digital Service Taxes; Interagency Labor Committee for Monitoring and Enforcement Procedural Guidelines for Petitions Pursuant to the USMCA; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order
H.R. 3, Lower Drug Costs Now Act of 2019 H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019 H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448/S. 99, Medicare Drug Price Negotiation Act H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1384, Medicare for All Act of 2019 H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019 H.R. 1425, Patient Protection and Affordable Care Enhancement Act H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019 H.R. 1985, Family Savings for Kids and Seniors Act H.R. 2207, Protect Medical Innovation Act of 2019 H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019 H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201, Families First Coronavirus Response Act H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 S. 12, Health Savings Act of 2019 S. 61, Safe and Affordable Drugs from Canada Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 64, Preserve Access to Affordable Generics and Biosimilars Act S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 S. 344, Hatch-Waxman Integrity Act of 2019 S. 470, Medicare at 50 Act S. 684, Middle Class Health Benefits Tax Repeal Act of 2019 S. 692, Protect Medical Innovation Act of 2019 S. 1416, Affordable Prescriptions for Patients Act of 2019 S. 1541, Tobacco-Free Youth Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act S. 3200, Chronic Disease Management Act of 2020 S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.) Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019) Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019) Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020) Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557; Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs; association health plans; importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations; balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; legislation addressing mental health parity; inclusion of prescription drug pricing on 2019 congressional agenda; reauthorization of the Patient Centered Outcomes Research Institute; (PCORI); potential premium reduction/reinsurance program to reduce health insurance premiums; proposals to expand Medicare including Medicare Buy-In and the development of a public option; medical hospital outpatient prospective payment system for CY 2020; drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates; potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty; comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements; comments on Medicare Program; modernizing and clarifying the physician self-referral regulations; comments on CMS proposed Medicaid fiscal accountability regulation; comments on CMS proposed transparency in coverage rule; comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d); comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program; Medicaid fiscal accountability regulation; comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D; transparency in coverage; issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies; Public Health and Social Services Emergency Fund (PHSSEF); health insurance coverage during the coronavirus pandemic; health legislative priorities for the potential Phase 4 coronavirus relief package; provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136); FCCs COVID-19 Telehealth Program; Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use; reform of the World Health Organization (WHO); continued U.S. membership in the World Health Organization Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19; potential legislation dealing with COVID-19 liability issues
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395/S. 4049, National Defense Authorization Act for Fiscal Year 2021 H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 H.R. 7669, Department of Homeland Security Appropriations Act, 2021, including provisions relating to printed circuit boards (PCBs S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); implementation of section 3610 of the Coronavirus Aid, Relief, and Economic Security (CARES) (P.L. 116-136); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) expedited contract closeout; Council of Defense and Space Industry Associations (CODSIA) Case 2020-006 - FAR Case 2019-009; prohibition on contracting with entities using certain telecommunications and video surveillance services or equipment; Council of Defense and Space Industry Associations (CODSIA) Defense Federal Acquisition Regulation Supplement (DFARS) services data collection - 2020-005, second draft, July 24, 2020; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 6395, National Defense Authorization Act for Fiscal Year 2021 S. 1790, National Defense Authorization Act for Fiscal Year 2020 Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy; Defense Federal Acquisition Regulation Supplement (DFARS) expediting contract closeout; section 889 of the National Defense Authorization Act; request for clarification of terms used in the Military End Use and Military End User (85 Fed. Reg. 23,459, April 28, 2020)
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 S.J.Res. 71, A joint resolution withdrawing approval of the Agreement Establishing the World Trade Organization Nomination of Paul Shmotolokha for First Vice President, Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); medicine and medical product supply chain; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; negotiations on the U.S.- Brazil trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to Africa, Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to COVID-19; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-Japan trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; Export-Import Bank (Ex-Im Bank); general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; domestic and international antitrust policy; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; Fiscal Year 2020 Customs and Boarder Protection supplemental; duty drawback claims; Generalized System of Preferences (GSP) reauthorization; Puerto Rico Electronic Export Information (EEI); comment period extension request on Section 232 investigation; U.S.-Brazil trade package; implementation of the Merchandise Processing Fee in the USMCA; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy American executive order; Executive Order 13920, Securing the United States Bulk-Power System; section 232 investigation into imports of laminations and wound cores for incorporation into transformers, electrical transformers, and transformer regulators
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Labor Statistics (BLS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
H.R. 739, Cyber Diplomacy Act of 2019 H.R. 764, United States Reciprocal Trade Act H.R. 940/S. 287, Bicameral Congressional Trade Authority Act of 2019 H.R. 948, No Oil Producing and Exporting Cartels Act of 2019 H.R. 1008/S. 365, Trade Security Act of 2019 H.R. 2219/S. 1188, Mongolia Third Neighbor Trade Act H.R. 3407, United States Export Finance Agency Act of 2019 H.R. 3843/S. 3026, Countering Russian and Other Overseas Kleptocracy Act H.R. 3960/S. 2303, Freedom for Americans to Travel to Cuba Act of 2019 H.R. 4140, Foreign Extortion Prevention Act H.R. 4695, Protect Against Conflict by Turkey (PACT) Act H.R. 4863, United States Export Finance Agency Act of 2019 H.R. 5430, United States-Mexico-Canada Agreement Implementation Act S. 2, Fair Trade with China Enforcement Act S. 482, Defending American Security from Kremlin Aggression Act of 2019 S. 1004, Securing America's Ports of Entry Act of 2019 S. 1060, Defending Elections from Threats by Establishing Redlines Act of 2019 S. 2641, Promoting American National Security and Preventing the Resurgence of ISIS Act of 2019 Nomination of Kimberly Reed to be a Member Board of Directors of the Export-Import Bank of the United States Nomination of Claudia Slacik to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Judith Delzoppo Pryor to be a Member of the Board of Directors of the Export-Import Bank of the United States Nomination of Spencer Bachus to be a Member of the Board of Directors of the Export-Import Bank of the United States Various issues relating to Trans-Pacific Partnership (TPP) Agreement; Transatlantic Trade and Investment Partnership (TTIP) negotiations; North American Free Trade Agreement (NAFTA) renegotiation; U. S.- Mexico-Canada (USMCA) trade agreement; United States-Mexico-Canada Agreement Implementation Act (P.L. 116-113); U.S.-Korea Free Trade Agreement (KORUS); reauthorization of the Generalized System of Preferences (GSP); the expanded use of software asset management by the Federal Government and its contractors; Trade in Services Agreement (TISA) negotiations; U.S.-Central Asia Trade and Investment Framework Agreement (TIFA); ratification of the Assignment of Receivables in International Trade Convention; reforms to Foreign Agents Registration Act (FARA) (P.L. 75-583); reforms to Lobbying Disclosure Act (LDA) (P.L. 104-65); reforms to export controls; Implementation of the FAA Reauthorization Act of 2018 Better Utilization of Investments Leading to Development (BUILD Act) (Public Law No: 115-254); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of Section 182 of the Trade Act of 1974 (P.L. 93-618), as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (the "Special 301 Report"); implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L. 111-203), G-20 obligations on Financial Service Reforms; Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); Section 301 of the Trade Act of 1974 (P.L. 93-618); International Emergency Economic Powers Act (IEEPA), Title II of Pub.L. 95-223; implementation of the African Growth and Opportunity Act (P.L. 106-200); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); negotiations on a U.S.- Kenya Free Trade Agreement; International Telecommunications Union; World Health Organization (WHO); World Intellectual Property Organization (WIPO); World Trade Organization (WTO) negotiations; efforts to reform the World Trade Organization; Government Procurement Act (GPA) at the World Trade Organization; implementation of World Trade Organizations Trade Facilitation Agreement (TFA); Defense Production Act of 1950 (P.L. 81-774); Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; plain packaging; USPTO IP Attache Program; China's intellectual property regime industrial policies and cybersecurity issues; implementation of the U.S.- China trade agreement; negotiations on the U.S.- India trade agreement; negotiations on the U.S.- Japan trade agreement; implementation of the U.S.- Japan trade agreement; IP issues relating to internet counterfeiting and piracy; IP issues relating to trade secret theft; IP issues relating to the United Nations high-level panel on access to medicines; IP issues relating to Australia, Brazil, Canada, China, India, Japan, Mexico, and Europe; IP issues relating to the U.S.-Mexico-Canada Agreement (USMCA); U.S.-Argentina economic and commercial relations; U.S.-Bangladesh economic and commercial relations; U.S.-Brazil economic and commercial relations; U.S.-Canada economic and commercial relations; U.S.-China economic and commercial relations; U.S.-Colombia economic and commercial relations; U.S.-Cuba economic and commercial relations; U.S.-Egypt economic and commercial relations; U.S.-Ghana economic and commercial relations; U.S.-India economic and commercial relations; U.S.-Indonesia economic and commercial relations; U.S.-Iraq economic and commercial relations; U.S.-Israel economic and commercial relations; U.S.-Japan economic and commercial relations; U.S.-Korea economic and commercial relations; U.S.-Mexico economic and commercial relations; U.S.-Nigeria economic and commercial relations; U.S.-Pakistan economic and commercial relations; U.S.-Russia economic and commercial relations; U.S.-South East Asia economic and commercial relations; U.S.-Turkey economic and commercial relations; U.S.-U.K. economic and commercial relations; U.S.-Vietnam economic and commercial relations; U.S. trade relations with the Middle East and North Africa; U.S. trade relations with Africa; U.S. sanctions on Russia; U.S. sanctions on Turkey; U.S.-EU privacy shield; U.S.-U.K. trade agreement; U.S.-EU trade agreement; U.S.-EU energy relations; U.S.-Switzerland economic and commercial relations; EU tax policy including digital tax proposals; Ukraine related sanctions; modernizing the Committee on Foreign Investment in the United States (CFIUS); Permanent Normal Trade Relations (PNTR) for Kazakhstan; reauthorization of the Export-Import Bank; general advocacy for Congress to reach a working quorum for the board of the Export-Import Bank; trade embargo with Cuba; trade policy consideration with regard to cross-border data flows and issues of forced localization; tax treaties with Hungary, Poland, Chile; International Monetary Fund (IMF) quota reform; funding for the Multilateral Development Banks (MDBs), including the World Bank, the African Development Bank (AfDB), the Asian Development Bank (ADB), the Inter-American Development Bank (IDB), the European Bank for Reconstruction and Development (EBRD) and the International Monetary Fund (IMF); international affairs budget; transatlantic investment, trade and regulatory cooperation; international concerns in the areas of antitrust, standards and investment; international trade and regulatory practices impacting digital goods and services; international artificial intelligence policy; international 5G policy; international cybersecurity policy; antitrust policy; advancing international regulatory cooperation; Internet Corporation for Assigned Names and Numbers (ICANN); steel and aluminum tariffs, including on China; customs and duties on electronic transmissions, particularly a proposal considered by the World Customs Organization (WCO); honey shipments from the nation of India held by CBP officials at ports of entry; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. United Kingdom; trade negotiations and trade priorities between the U.S. Japan; proposed rules implementing Executive Order 13873, Securing the Information and Communications Technology and Services Supply Chain; suspension of Title III of the Cuban Liberty and Democracy Solidarity Act of 1996 (P.L. 104-114); comments on U.S. Customs and Border Protection 21st century customs framework initiative; comments on proposed rulemaking for customs broker verification and importers identification; comments on fabricated structural steel from Canada, China, and Mexico; supplemental funding for additional Customs and Border Protection (CBP) officers at ports-of-entry; U.S. Trade Representative on initiation of section 301 investigation of Frances digital services tax; potential Buy America executive order; effects of imports of uranium on national security
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); implementation of the National Defense Authorization Act for Fiscal Year 2020 (P.L. 116-92); reforms to Foreign Assistance Act (P.L. 87-195); export controls; U.S. Conventional Arms Transfer (CAT) Policy
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Labor Statistics (BLS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council of Economic Advisers (CEA), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
S. 1790, National Defense Authorization Act for Fiscal Year 2020 Proposed rule on operation of small unmanned aircraft systems over people, (84 Fed. Reg. 3,856-3,907, February 13, 2019) Advance notice of proposed rulemaking on safe and secure operations of small unmanned aircraft systems, (84 Fed. Reg. 3,732-3,739, February 13, 2019) Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); Implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); Implementation of the Foreign Assistance Act (P.L. 87-195); Implementation of the FAA Reauthorization Act of 2018 (P.L. 115-252); unmanned aerial systems, and FAA exemptions for commercial operations of UAS; urban air mobility; Reforms to export controls; U.S. Conventional Arms Transfer (CAT) Policy
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 2500/S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); reforms to Foreign Assistance Act (P.L. 87-195); procurement policy; export controls; U.S. Conventional Arms Transfer (CAT) Policy
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Labor Statistics (BLS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
H.R. 1033, Return Expenses Paid and Yielded (REPAY) Act H.R. 2500/S. 1790, National Defense Authorization Act for Fiscal Year 2020 Nomination of Barbara Barrett to be Secretary of the Air Force Various issues relating to implementation of the Countering Americas Adversaries Through Sanctions Act (P.L. 115-44); implementation of the John S. McCain National Defense Authorization Act for Fiscal Year 2019, Title XVII, Foreign Investment Risk Review Modernization Act (P.L. 115-232); reforms to Foreign Assistance Act (P.L. 87-195); procurement policy; export controls; U.S. Conventional Arms Transfer (CAT) Policy
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Social Security Administration (SSA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of the Comptroller of the Currency (OCC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Social Security Administration (SSA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Filing targets: Agency for Toxic Substances & Disease Registry, Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of the Comptroller of the Currency (OCC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), Social Security Administration (SSA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Fish & Wildlife Service (USFWS), U.S. Trade Representative (USTR), White House Office
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office